Symbols / MPLT Stock $29.76 +2.23% MapLight Therapeutics, Inc.
MPLT (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Ratings
Current target
$29.76
Low
$28.00
High
$37.00
Mean
$32.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-08 | init | Needham | — → Buy | $37 |
| 2026-04-07 | init | TD Cowen | — → Buy | — |
| 2026-03-19 | init | Canaccord Genuity | — → Buy | $35 |
| 2025-11-21 | init | Jefferies | — → Buy | $32 |
| 2025-11-21 | init | Leerink Partners | — → Outperform | $30 |
| 2025-11-21 | init | Stifel | — → Buy | $28 |
| 2025-11-21 | init | Morgan Stanley | — → Overweight | $34 |
- Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat hu, 23 Apr 2026 03
- What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data - Yahoo Finance Wed, 22 Apr 2026 18
- Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 12.8% - Still a Buy? - MarketBeat Wed, 22 Apr 2026 18
- MapLight Therapeutics (MPLT) CFO sells 2,922 shares mainly for tax withholding - Stock Titan Fri, 17 Apr 2026 20
- MapLight Therapeutics (MPLT): The best healthcare stock insiders are buying - MSN Mon, 13 Apr 2026 10
- MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying - Yahoo Finance Sun, 12 Apr 2026 07
- RSU settlement: MapLight Therapeutics (NASDAQ: MPLT) vested 7,305 shares - Stock Titan Wed, 15 Apr 2026 21
- Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down - Here's Why - MarketBeat ue, 21 Apr 2026 16
- TD Cowen Initiates on MapLight (MPLT); Says It’s Undervalued on Schizophrenia Alone - Yahoo Finance Mon, 20 Apr 2026 14
- MapLight (NASDAQ: MPLT) counsel sells 1,827 shares mainly to cover taxes - Stock Titan Fri, 17 Apr 2026 20
- Maplight Therapeutics (NASDAQ:MPLT) Hits New 52-Week High - What's Next? - MarketBeat hu, 23 Apr 2026 09
- [144] MapLight Therapeutics, Inc. SEC Filing - Stock Titan Wed, 15 Apr 2026 07
- Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat ue, 21 Apr 2026 13
- MapLight (MPLT) director sells 8,593 shares under 10b5-1 plan - Stock Titan Fri, 17 Apr 2026 07
- MapLight Therapeutics (MPLT) CMO sells 3,213 shares for tax withholding - Stock Titan Fri, 17 Apr 2026 20
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Total Revenue |
|
0.00
|
| Operating Revenue |
|
0.00
|
| Operating Expense |
|
169.08
|
| Research And Development |
|
138.35
|
| Selling General And Administration |
|
30.73
|
| General And Administrative Expense |
|
30.73
|
| Salaries And Wages |
|
21.69
|
| Other Gand A |
|
9.05
|
| Total Expenses |
|
169.08
|
| Operating Income |
|
-169.08
|
| Total Operating Income As Reported |
|
-169.08
|
| EBITDA |
|
-168.50
|
| Normalized EBITDA |
|
-168.50
|
| Reconciled Depreciation |
|
0.58
|
| EBIT |
|
-169.08
|
| Net Income |
|
-161.15
|
| Pretax Income |
|
-161.15
|
| Net Non Operating Interest Income Expense |
|
5.52
|
| Net Interest Income |
|
5.52
|
| Interest Income Non Operating |
|
5.52
|
| Interest Income |
|
5.52
|
| Other Income Expense |
|
2.41
|
| Other Non Operating Income Expenses |
|
2.41
|
| Tax Rate For Calcs |
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-161.15
|
| Net Income From Continuing Operation Net Minority Interest |
|
-161.15
|
| Net Income From Continuing And Discontinued Operation |
|
-161.15
|
| Net Income Continuous Operations |
|
-161.15
|
| Normalized Income |
|
-161.15
|
| Net Income Common Stockholders |
|
-161.15
|
| Diluted EPS |
|
—
|
| Basic EPS |
|
—
|
| Basic Average Shares |
|
—
|
| Diluted Average Shares |
|
—
|
| Diluted NI Availto Com Stockholders |
|
-161.15
|
| Earnings From Equity Interest |
|
0.00
|
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Total Assets |
|
479.51
|
| Current Assets |
|
324.67
|
| Cash Cash Equivalents And Short Term Investments |
|
305.10
|
| Cash And Cash Equivalents |
|
46.73
|
| Other Short Term Investments |
|
258.37
|
| Other Current Assets |
|
19.57
|
| Total Non Current Assets |
|
154.84
|
| Net PPE |
|
6.58
|
| Gross PPE |
|
9.22
|
| Accumulated Depreciation |
|
-2.64
|
| Machinery Furniture Equipment |
|
0.63
|
| Other Properties |
|
8.60
|
| Investments And Advances |
|
147.99
|
| Other Non Current Assets |
|
0.27
|
| Total Liabilities Net Minority Interest |
|
21.14
|
| Current Liabilities |
|
16.23
|
| Payables And Accrued Expenses |
|
9.18
|
| Payables |
|
3.29
|
| Accounts Payable |
|
3.29
|
| Current Accrued Expenses |
|
5.89
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
6.16
|
| Current Debt And Capital Lease Obligation |
|
0.89
|
| Current Capital Lease Obligation |
|
0.89
|
| Current Deferred Liabilities |
|
0.00
|
| Current Deferred Revenue |
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
4.91
|
| Long Term Debt And Capital Lease Obligation |
|
4.91
|
| Long Term Capital Lease Obligation |
|
4.91
|
| Stockholders Equity |
|
458.37
|
| Common Stock Equity |
|
458.37
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
44.02
|
| Ordinary Shares Number |
|
44.02
|
| Additional Paid In Capital |
|
819.12
|
| Retained Earnings |
|
-360.52
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.23
|
| Other Equity Adjustments |
|
-0.23
|
| Total Equity Gross Minority Interest |
|
458.37
|
| Total Capitalization |
|
458.37
|
| Working Capital |
|
308.44
|
| Invested Capital |
|
458.37
|
| Total Debt |
|
5.80
|
| Capital Lease Obligations |
|
5.80
|
| Net Tangible Assets |
|
458.37
|
| Tangible Book Value |
|
458.37
|
| Available For Sale Securities |
|
147.99
|
| Investmentin Financial Assets |
|
147.99
|
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Operating Cash Flow |
|
-138.14
|
| Cash Flow From Continuing Operating Activities |
|
-138.14
|
| Net Income From Continuing Operations |
|
-161.15
|
| Depreciation Amortization Depletion |
|
0.58
|
| Depreciation |
|
0.58
|
| Depreciation And Amortization |
|
0.58
|
| Other Non Cash Items |
|
1.36
|
| Stock Based Compensation |
|
36.01
|
| Operating Gains Losses |
|
0.01
|
| Gain Loss On Sale Of PPE |
|
0.01
|
| Change In Working Capital |
|
-12.84
|
| Change In Prepaid Assets |
|
-13.10
|
| Change In Payables And Accrued Expense |
|
4.28
|
| Change In Accrued Expense |
|
2.90
|
| Change In Payable |
|
1.38
|
| Change In Account Payable |
|
1.38
|
| Change In Other Working Capital |
|
-3.24
|
| Change In Other Current Liabilities |
|
-0.78
|
| Investing Cash Flow |
|
-323.21
|
| Cash Flow From Continuing Investing Activities |
|
-323.21
|
| Net PPE Purchase And Sale |
|
-0.47
|
| Purchase Of PPE |
|
-0.47
|
| Capital Expenditure |
|
-0.47
|
| Net Investment Purchase And Sale |
|
-322.73
|
| Purchase Of Investment |
|
-408.23
|
| Sale Of Investment |
|
85.50
|
| Financing Cash Flow |
|
469.82
|
| Cash Flow From Continuing Financing Activities |
|
469.82
|
| Proceeds From Stock Option Exercised |
|
0.28
|
| Net Other Financing Charges |
|
-5.02
|
| Changes In Cash |
|
8.48
|
| Beginning Cash Position |
|
38.46
|
| End Cash Position |
|
46.94
|
| Free Cash Flow |
|
-138.61
|
| Amortization Of Securities |
|
-2.10
|
| Earnings Losses From Equity Investments |
|
0.00
|
| Issuance Of Capital Stock |
|
474.56
|
| Net Preferred Stock Issuance |
|
474.56
|
| Preferred Stock Issuance |
|
474.56
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-17 View
- 42026-04-17 View
- 42026-04-17 View
- 42026-04-17 View
- 42026-04-17 View
- 42026-04-17 View
- 42026-04-17 View
- 42026-04-17 View
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 42026-02-24 View
- 42026-02-20 View
- 42026-02-18 View
- 42026-02-12 View
- 42026-02-12 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|